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Background: The development of immunotherapy has led to significant progress in the treatment of metastatic
cancer, including the development of genetic engineering technologies that redirect lymphocytes to recognize and
target a wide variety of tumor antigens. Chimeric antigen receptors (CARs) are hybrid proteins combining antibody
recognition domains linked to T cell signaling elements. Clinical trials of CAR-transduced peripheral blood lymphocytes
(PBL) have induced remission of both solid organ and hematologic malignancies. Chondroitin sulfate proteoglycan 4
(CSPG4) is a promising target antigen that is overexpressed in multiple cancer histologies including melanoma,
triple-negative breast cancer, glioblastoma, mesothelioma and sarcoma.
Methods: CSPG4 expression in cancer cell lines was assayed using flow cytometry (FACS) and reverse-transcription PCR
(RT-PCR). Immunohistochemistry was utilized to assay resected melanomas and normal human tissues (n = 30) for
CSPG4 expression and a reverse-phase protein array comprising 94 normal tissue samples was also interrogated for
CSPG4 expression. CARs were successfully constructed from multiple murine antibodies (225.28S, TP41.2, 149.53) using
second generation (CD28.CD3ζ) signaling domains. CAR sequences were cloned into a gamma-retroviral vector with
subsequent successful production of retroviral supernatant and PBL transduction. CAR efficacy was assayed by cytokine
release and cytolysis following coculture with target cell lines. Additionally, glioblastoma stem cells were generated
from resected human tumors, and CSPG4 expression was determined by RT-PCR and FACS.
Results: Immunohistochemistry demonstrated prominent CSPG4 expression in melanoma tumors, but failed to
demonstrate expression in any of the 30 normal human tissues studied. Two of 94 normal tissue protein lysates were
positive by protein array. CAR constructs demonstrated cytokine secretion and cytolytic function after co-culture with
tumor cell lines from multiple different histologies, including melanoma, breast cancer, mesothelioma, glioblastoma
and osteosarcoma. Furthermore, we report for the first time that CSPG4 is expressed on glioblastoma cancer stem cells
(GSC) and demonstrate that anti-CSPG4 CAR-transduced T cells recognize and kill these GSC.
Conclusions: The functionality of multiple different CARs, with the widespread expression of CSPG4 on multiple
malignancies, suggests that CSPG4 may be an attractive candidate tumor antigen for CAR-based immunotherapies
using appropriate technology to limit possible off-tumor toxicity.
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The development of the field of immunotherapy has led
to significant progress in the treatment of metastatic
cancer. The most effective immunotherapy treatment
option to date is the adoptive cell transfer (ACT) of au-
tologous tumor-infiltrating lymphocytes (TIL) that can
induce complete durable regression of metastatic mela-
nomas [1]. This therapy necessitates the surgical resec-
tion of a tumor deposit and subsequent generation of
TIL, which is not possible in every patient, and to date
has shown limited applicability in histologies other than
melanoma.
Genetic engineering technologies that allow for the
redirection of lymphocytes to recognize and target a
variety of tumor antigens has created new possibilities
for the utilization of immunotherapy to treat metastatic
cancer. T cell receptor (TCR) genes that target specific
tumor antigens have been inserted into peripheral blood
lymphocytes (PBL) and, when transfused back into pa-
tients in conjunction with administration of high-dose
interleukin-2 after non-myeloablative chemotherapy,
have been shown to effect tumor regression in patients
with melanoma and synovial cell sarcoma [2-5]. Chimeric
antigen receptors (CARs) have also been investigated as
an alternative way to redirect T cells to recognize and des-
troy tumor cells. Comprised of a single-chain variable
fragment (scFv) from a monoclonal antibody linked to
intracellular T cell signaling domains, these fusion
proteins are able to effect antigen recognition in a
manner that is not restricted to the major histocom-
patibility complex, conferring a distinct advantage over
TCRs [6-8]. CAR-transduced T cells have been shown
to induce remission of both solid organ and hematologic
malignancies [9-15].
We sought to develop an optimally effective CAR to
target chondroitin sulfate proteoglycan 4 (CSPG4).
Formerly known as High Molecular Weight-Melanoma
Associated Antigen (HMW-MAA), this highly immuno-
genic cell surface proteoglycan was identified on melan-
oma cells in the 1970’s and has been shown to facilitate
the progression from radial to vertical growth in melan-
oma tumors [16-18]. It has also shown overexpression
and potential as an immunotherapy target on a number
of other tumor histologies including triple-negative
breast cancer, head and neck squamous cell cancer,
mesothelioma and glioblastoma [16,19-21]. Our previous
work demonstrated the ability to construct a CSPG4-
specific CAR using the murine monoclonal antibody
(mAb) 225.28S. PBL transduced with the 225.28S CAR
demonstrated cytokine secretion and cytolytic function
when co-cultured with melanoma cell lines in vitro and
were reactive against explanted human melanomas [22].
Herein we expand upon that work by utilizing different
murine mAbs reactive against CSPG4 to construct CARsthat target cell lines from multiple tumor histologies as
well as cancer stem cells (CSC).
Results
CSPG4 expression in tumor cell lines and normal tissues
Cell lines from multiple histologies were studied for
CSPG4 expression by fluorescence-activated cell sorting
analysis (FACS) (Figure 1). Six of the 8 melanoma lines
were strongly positive for CSPG4 expression with an
additional line, mel624.38, demonstrating intermediate
expression. Of the 6 glioblastoma cell lines assayed, 3
demonstrated CSPG4 expression, as did 2 of the 4
triple-negative breast cancer cell lines. To further
analyze CSPG4 expression in tumors and normal tis-
sues, we used immunohistochemistry and protein array
technology for antigen detection. Immunohistochemis-
try using antibody TP41.2 failed to demonstrate any
significant staining on a normal tissue panel, with 30
normal tissue types tested, but showed antibody stain-
ing of melanoma samples in a membranous pattern
(Figure 2). To further analyze CSPG4 antigen expres-
sion we used a reverse-phase protein array technology,
which immobilizes protein lysates from frozen normal
tissues on a carbon fiber surface. Antibody TP41.2 was
again used for detection and after normalization for
loading with beta-actin, the threshold level for antigen
expression was set to the mean background level plus
one standard deviation (value, 1.203). In this assay the
relative CSPG4 antigen expression in three melanoma
samples was 4.668, 9.665, and 24.041 (Figure 3). Of 94
normal tissues tested, we observed CSPG4 antigen de-
tection above the threshold level in 2 of 4 small bowel
samples (values, 1.982 and 2.875, Figure 3).
CARs from murine antibodies recognize cell lines from
multiple cancer histologies
CARs were constructed from four different murine scFv
fragments: 225.28S, TP41.2, 149.53 and G71.1 all of
which have demonstrated reactivity with CSPG4 [23-25].
These were cloned into a MSGV1-based retroviral vec-
tor with the CD28.CD3ζ signaling domains and then
transduced into PBL from different donors. The CARs
from the mAbs 225.28S, TP41.2 and 149.53 antibodies
were detected on the surface of transduced PBL by
FACS, whereas the CAR from the G71.1 antibody was
not (Figure 4A). DNA sequence analysis of the G71.1
CAR vector did not reveal any cause for the lack of ex-
pression. The three CARs that demonstrated surface ex-
pression on PBL also demonstrated IFN-γ release when
cocultured with the CSPG4-expressing melanoma lines
mel1300 and mel888 (Figure 4B). Though cytokine re-
lease varied between PBL donors, cytokine release from
the TP41.2-CD28.CD3ζ construct was consistently high
in all three donors.
Figure 1 CSPG4 expression in tumor cell lines from multiple histologies by FACS. Fluorescence-activated cell sorting analysis (FACS) was
performed using a conjugated mAb (anti-hNG2/MCSP) specific for human chondroitin sulfate proteoglycan 4 (CSPG4) according to manufacturers’
recommendations (R&D Systems, Minneapolis, MD). Representative isotype controls are shown in the top left hand panels. Cell lines and percent
expression were as identified.
Figure 2 Immunohistochemistry demonstrates staining of melanoma tumors and no staining of any normal tissues. Staining was done
with the TP41.2 antibody. 30 normal tissues [adrenal, bladder, bone marrow, breast (5 samples), cerebellum, cerebrum grey matter, cerebrum
white matter, colon (2 samples), esophagus, heart, kidney cortex, kidney medulla, liver (2 samples), lung (2 samples), lymph node, mesothelium,
muscle, ovary, pancreas, peripheral nerve, prostate, salivary gland, skin (2 samples), small bowel, spleen, stomach, testis, thyroid, uterus
endometrium, uterus myometrium] were tested with representative data shown here. Magnification shown is 40X.
Beard et al. Journal for ImmunoTherapy of Cancer 2014, 2:25 Page 3 of 11
http://www.immunotherapyofcancer.org/content/2/1/25
































Relative CSPG4 Expression Signal
Figure 3 (See legend on next page.)
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Figure 3 Reverse-phase protein array. Total proteins were extracted from frozen tissues and applied to Multi-Spot™ plates (see Methods). Anti-CSPG4
(TP41.2) and anti-Actin antibodies were applied and following incubation and wash, detected with SULFO-TAG™ antibodies. Signal was normalized to actin
expression and is expressed as relatively fold over background (water). The horizontal dashed line is the threshold antigen detection value set as the
background mean plus one standard deviation. Each bar is protein from a different donor from the indicated tissues.
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three reactive CARs and cocultured with CSPG4-positive cell
lines from multiple different histologies including the
glioblastoma cell line A1207, the breast cancer cell line
MDAMB231, the mesothelioma cell line Mill, the osteosar-
coma cell line MgG-63 and the melanoma line mel938. Each
of the CSPG4 CAR transduced PBL cultures yielded IFN-γ
effector cytokine release with considerably lower levels ob-
served with the CSPG4-negative non-small cell lung cancer
line H1299 (Figure 5). Again the CAR constructed from the
TP41.2 antibody was the most reactive overall.
We next determined the ability of the CSPG4 CAR trans-











































Figure 4 Murine CARs targeting CSPG4. Transduction efficiencies by FACS
Data shown is representative of FACS data from three different PBL donors. Cell
cytokine release. IFN-γ release when transduced PBL were co-cultured with CSP
cell lines. Anti-CSPG4 CAR-transduced T cells activity was statistically significant (
cells with the exception of 225.28 s transduced T cells from donor 2 (p > 0.05).TP41.2-based CSPG4 CAR transduced T cells were cocul-
tured with either melanoma line mel1300 or glioblastoma
cell line LN443. Cocultures were performed with two diffe-
rent donor T cells and included the H1299 negative control
cell line and GFP transduced T cells as a specificity control.
Results presented in Figure 6 demonstrate that both donor
T cells were capable of producing three effector cytokines;
interferon-gamma (IFN-γ), tumor necrosis factors alpha
(TNF-α), and granulocyte macrophage colony stimulating
factor (GM-CSF). These effector cytokine production was
specific to tumor lines expressing CSPG4, as minimal
cytokine was release in coculture with H1299 cells or with


































was determined using goat α-mouse Fab staining (A) for CAR detection.
s were cocultured with melanoma tumor cell lines to determine effector
G4-positive melanoma target lines (B). Mel888 and mel1300 =melanoma











































































GFP 225.28S TP41.2 149.53
Figure 5 PBL transduced with murine CARs targeting CSPG4 recognize tumor lines from multiple cancer histologies. All CARs shown
use the second generation CD28.CD3ζ signaling domain. A1207 = glioblastoma multiforme cell line, Mill = mesothelioma, MDAMB231 = breast
cancer cell lines, MgG-63 = osteosarcoma cell line, mel938 =melanoma cell lines, H1299A = non-small cell lung cancer line (negative control).
Anti-CSPG4 CAR-transduced T cells activity was statistically significant (p < 0.05, student’s t-test) in all comparisons to GFP control transduced T
cells versus H1299 cells from donor 4. Anti-CSPG4 CAR-transduced T cells activity was statistically significant (p < 0.05) in all comparisons of TP41.2
and 149.53 CAR transduced cells to GFP control transduced T cells versus H1299 cells from donor 5. There was no significant difference in activity of
225.28S CAR transduced cells to GFP control transduced T cells versus H1299 cells from donor 5 in cocultures with MgG-63 and mel938 cells (p > 0.05).
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recognized by CSPG4-targeting CAR transduced cells
CSPG4 expression in glioblastoma cell lines motivated us
to query a large database of gene expression in human
brain tumor samples (Rembrandt database, National
Cancer Institute, http://rembrandt.nci.nih.gov) [26].
Compared to adjacent non-tumor tissues, CSPG4 was
overexpressed in all brain tumors samples (Figure 7A).
Glioblastoma cell lines have been previously shown to


























Figure 6 CAR transduced T cell produce multiple effector cytokines. T
(donors 6 and 7) were cocultured with melanoma (mel1300) and glioblasto
(H1299 was used as a CSPG4 negative control line). IFN-γ, TNF-α, and GMCSF
Anti-CSPG4 CAR-transduced T cells activity (stripped bars) was statistically sign
bars) transduced T cells.primary brain tumors. Alternatively, glioma stem cells (GSC)
lines derived from primary tumors and grown as gliospheres
have been shown to be much more representative of pri-
mary tumors [27]. Using multiple GSC lines (Figure 7B),
we determined that these lines expressed CSPG4 by both
FACS (Figure 7C) and RT-PCR based assays (Figure 7D).
We initiated coculture experiments to determine if
CSPG4 CAR-engineered T cells recognized these GSC
lines and observed that CSPG4 CAR transduced cells rec-












1 2299 LN443 H1299 LN443
TNF- GM-CSF
TNF-
P41.2 anti-CSPG4 CAR transduced T cells from two different donors
ma (LN443) tumor cell lines to determine effector cytokine release
production was determined by ELISA (mean of triplicate determinations).
ificant (p < 0.05, student’s t-test) in all comparisons to GFP control (black
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gliospheres with 51Cr, we also determined that three of
three GSC lines tested could be specifically lysed by
CSPG4 CAR transduced T cells (Figure 8B).
Discussion
CSPG4 is an antigen that has been widely studied and
has previously been suggested as a target for immuno-
therapy. It is expressed on a high percentage of melanomas,
greater than 80% in some reports, and immunohistoche-
mistry demonstrates expression in several other malignan-
cies, including triple-negative breast cancer, glioblastoma,
head and neck squamous cell carcinoma, sarcoma and
mesothelioma [16,21,28,29]. Studies have demonstrated the
effectiveness of targeting CSPG4 with monoclonal antibody
(mAb)-based immunotherapy, both in vitro and in mouse
models, to treat melanoma, triple-negative breast cancer,
and mesothelioma [19,21,30]. To date, CSPG4 has only
been targeted in human trials in the form of mouse
anti-idiotypic monoclonal antibodies and vaccines that,
though safe, proved mostly ineffective for long-term
cancer remission [31-33]. Given the recent success of
CAR-based therapies, the development of a safe and ef-
fective CAR targeting CSPG4 is certainly appealing.
In this study we have generated CSPG4-targeting
CARs from multiple different murine monoclonal anti-
bodies. PBL transduced with these CARs demonstrate
cytokine release and cytolytic function when co-cultured
with tumor cell lines from different cancer histologies.A
C
308 – IsotypeControl 308 – CSPG4 Expr
IgG -CSPG4
Figure 7 CSPG4 has potential to treat brain malignancies. (A) CSPG4 g
tumors by Affymetrix analysis. Data from the Rembrandt database. Nationa
nih.gov. Accessed 2013 April 12. (B) Glioblastoma stem cells generated from
by RT-PCR (D). Representative data shown.Of the monoclonal antibodies studied, TP42.1 demon-
strated the most consistent expression and reactivity
among varying PBL donors. In these experiments, we
utilized the well characterized second generation CAR
design consisting of the CD28 costimulatory domain
linked to the intracellular T cell receptor signaling chain
CD3zeta. As CAR technology becomes increasingly so-
phisticated, the potential benefits various T cell signaling/
costimulatory domains, including improved antitumor ac-
tivity and prolonged survival of modified T cells, will con-
tinue to be explored [6,34]. Though it is not yet clear what
the optimal combination and arrangement of additional
intracellular signaling domains, such as 41BB or CD27
may be, the ability to successfully target tumor cell lines
with variety CSPG4-directed CARs is promising [35].
Most recently, Geldres et al., reported data with a different
mAb-based CSPG4 CAR, and demonstrated similar bio-
logical activity, but did not target CSC [36]. These investi-
gators confirmed the result presented herein that in a
large panel of normal tissues (n = 33), CSPG4 expression
was not observed by immunohistochemistry. In the data
reported herein, we used a more sensitive reverse-phase
protein array technology and demonstrated 2 of 4 small
bowel samples had signals above background.
CSPG4 expression has previously been demonstrated
on CSCs derived from squamous cell carcinoma of the
head and neck and basal breast carcinomas [16]. This
study demonstrates CSPG4 expression on GSCs as well.
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Figure 8 CSPG4 CAR recognition of glioma stem cells. (A) PBL from 3 donors were transduced with anti-CSPG4 murine CAR 225.28S-CD28.
CD3ζ and co-cultured with the indicated GSC lines. Shown is the resultant IFN-γ release (pg/ml) following overnight co-culture (values are the
average of duplicate determinations). (B) CSPG4 CAR-transduced PBL were mixed with the indicated GSC lines at various effector to target ratios
and cytolytic function determined (shown as percent specific lysis). Data are representative of duplicate determinations.
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tion kinetics, immunohistochemistry, histopathology and
gene expression profiling [27]. They demonstrated more
similarities to human glioblastomas than do traditional
tumor cell lines. CSCs have been shown to effect tumor
recurrence and development of metastatic disease, ex-
hibit characteristics of self-renewal and resistance to
chemotherapy and radiotherapy, and can induce tumor
formation in immunodeficient mice [37]. Tumor eradi-
cation may ultimately require targeting CSCs, therefore
the ability of a therapy to recognize and kill these cells is
important. In this study, an anti-CSPG4 CAR demon-
strated recognition and cytolysis of multiple GSC lines, a
finding with potential therapeutic implications.
CSPG4 could be an attractive immunotherapy target
given its expression on a high percentage of melanomas as
well as many other cancer histologies and cancer stem cells.
Of potential concern though, is the observation of low-level
antigen expression on two of 94 normal tissues samples
(both from small bowel) as determined by reverse-phase
protein array (Figure 3). On-target/off-tumor toxicity is a
known property of CAR engineered T cells and has been
observed in renal cell carcinoma, colorectal cancer and B
cell malignancies [10,38,39]. To limit potential toxicities, it
may be possible to target multiple antigens or to engineer
T cells with a suicide gene safety switch to potentially man-
age deleterious recognition of normal tissues.
Conclusions
Multiple variations of CSPG4-targeting CARs were de-
scribed in this study, utilizing several murine monoclonal
antibodies. CAR-transduced PBL successfully recognized
and killed tumor cell lines from multiple different cancerhistologies as well as glioblastoma-derived CSCs. CSPG4
has significant potential as an immunotherapy target, as
supported by its expression on a high percentage of mel-
anomas and its prevalence in other cancer histologies and
CSCs, as well as, its general lack of expression on normal
tissues as demonstrated by immunohistochemistry. The
recent success of CAR therapies suggests that with appro-
priate safety modifications, we can be cautiously optimistic
regarding the potential development of a CSPG4-
specific CAR therapy for the treatment of metastatic
cancer.
Methods
Tumor and normal tissue samples, cell lines, and
lymphocytes
All human cells and tissues were obtained under Internal
Review Board approved protocols (National Cancer
Institute, Bethesda, MD). Tumor cell lines were grown
under standard conditions in Roswell Park Memorial
Institute (RPMI) 1640 or Dulbecco’s Modified Eagle
Medium (DMEM) (Invitrogen, Carlsbad, CA) with
10% fetal bovine serum (FBS) medium (Sigma Aldrich,
St. Louis, MO), 25 mM Hepes (Invitrogen) and 100U/μg
per mL of penicillin/streptomycin (Invitrogen) at 37°C in
a 5% CO2 atmosphere. Peripheral blood lymphocytes
(PBL) were collected via leukapharesis. Lymphocytes were
maintained in AIM-V medium (Invitrogen) supplemented
with 5% human antibody serum (Valley Biomedical,
Winchester, VA), 25 mM Hepes (Invitrogen), 100U/μg
per mL of penicillin/streptomycin (Invitrogen), and
300 IU/mL interleukin-2 (Aldesleukin, Prometheus, San
Diego, CA). Description of tumor cell lines and CSPG4
expression was as previously reported (17–22).
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RNA isolation was performed using a RNeasy Mini Kit
(Qiagen, Valencia, CA). Reverse transcription (RT) was
performed using a High Capacity cDNA Reverse Tran-
scription Kit (Applied Biosystems, Grand Island, NY).
Quantitative PCR was performed with the TaqMan Fast
Universal PCR Master Mix (Applied Biosystems, Grand
Island, NY) and the use of a 7500 Fast Real-Time PCR
System (Applied Biosystems, Grand Island, NY). Copy
numbers were determined using a standard curve gene-
rated from the CSPG4 plasmid and results were norma-
lized against β-actin (ACTB).Immunohistochemistry
Immunohistochemistry was performed on a normal tis-
sue panel and tumor slides following paraffinization in
xylene and graded alcohol. A panel of anonymous
human normal tissue and melanomas obtained from the
Tissue Array Research Program (Laboratory of Pathology,
National Cancer Institute, Bethesda, MD) was used to
construct a “mini-TMA” of 1.5 mm cores. Antigen
retrieval was performed in pH 9 AfR buffer (Dako,
Carpinteria, CA) for 20 minutes in a pressure cooker.
The TP41.2 antibody was used at a concentration of
1:100 at room temperature for 60 minutes, followed by
Detection Envision + (Dako) DAB for 10 minutes,
followed by dehydration and a coverslip. A negative
control with no primary antibody was performed, and a
melanoma sample was used as a primary control.Well-based reverse-phase protein array
Total proteins were extracted from three 10 μm frozen tis-
sue sections using T-PER buffer (Pierce Biotechnology)
with proteinase inhibitor cocktail (1 tablet/25 ml, Roche).
Two μg protein extract from frozen tissue specimen was
added to Meso Scale Discovery (MSD, Gaithersburg, MD)
Multi-Spot™ plates (MA2400 96 HB Plate), the plate was
allowed to dry at room temperature for 90 min, and the
plates were subsequently further incubated for 30 min at
37°C. The antigen-coated plates were preincubated with
3% nonfat milk in PBST for 60 min at RT before primary
antibody reactions. Anti-CSPG4 (TP41.2) and anti-Actin
(Abnova, mouse, clone 3G4-F9) were diluted 1:1000 and
1:5000 respectively, with 3% BSA in PBST, and then incu-
bated overnight at 4°C. After washing with PBST, the
plates were incubated for 1 h with goat anti-mouse
SULFO-TAG™ antibodies at a dilution of 1:2000 (0.5 μg/ml)
with 5% nonfat milk in PBST. The plates were then aspi-
rated and washed three times with PBST. Finally, MSD-T
read buffer was added to the plates and they were read
on the MSD Sector Imager 2400 reader (Meso Scale
Discovery). BSA coated wells were included on each
plate as a control for non-specific binding effects.Signal was normalized to actin expression and is
expressed as relatively fold over background (water).
Generation of chimeric antigen constructs, retroviral
supernatant production and T-cell transduction
The scFvs derived from the murine mAb 225.28S,
TP41.2, 149.53 and G71.1 (references, 23–25, and pa-
tent number US 6,924,359) were synthesized as codon-
optimized CARs using peptide linkers 218 (sequence
G2TSGSGKPGSGEGS) or g4s (sequence GGGGSGGG
GSGGGGS) with signaling domains CD28.CD3ζ (Blue
Heron Bio, Bothell, WA) [23-25]. The precise antigen
binding domains of these mAbs were not determined.
The complete scFv sequence was cloned into MSGV-
4D5-28z vector backbone after removal of the 4D5 scFv,
with production of retroviral supernatant and PBL
transduction performed as previously described (the
complete amino acid sequence of the CD28-CD3zeta
signaling domains used was described in the supple-
mental data to Zhao et al.) [40].
Flow cytometry and functional assays
FACS was performed using a conjugated mAb (anti-
hNG2/MCSP) specific for human chondroitin sulfate
proteoglycan 4 (CSPG4) according to manufacturers’
recommendations (R&D Systems, Minneapolis, MD). To
assess for transduction efficiencies, protein L staining was
used as previously described [41] as were F(ab’)2 fragment
goat anti-mouse IgG antibodies (Jackson Immunore-
search, West Grove, PA), according to manufacturers rec-
ommendations. Cytokine secretion assays were done as
previously described [40]. Cytolysis was assessed by either
51Cr assay, as previously described [40], or by CytoTox-
Glo™ bioluminescence assay (Promega, Madison, WI),
which utilizes the luminogenic AAF-Glo™ Substrate to
measure dead-cell protease activity that generates a lu-
minescent signal proportional to the number of lysed
cells in a sample. Effector and target cells were coincu-
bated at 37°C for 4 h. Bioluminescence release was
measured and specific lysis was calculated according to
the following formula: percent specific lysis = [specific
release – (spontaneous effector release + spontaneous
target release)]/total target release – spontaneous target
release × 100%, average of triplicate samples.
Generation of glioblastoma stem cells
Glioblastoma stem cells (GSCs) were generated from
tumors by enzymatic digestion into single cells and
subsequent growth in NBE medium, comprised of
Neurobasal-A medium (Invitrogen, Carlsbad, CA) sup-
plemented with N2 and B27 (Invitrogen), bFGF and
epidermal growth factors (R&D Systems, Minneapolis,
MN) as previously described [27,42].
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